Maia Biotechnology Stock Investor Sentiment

MAIA Stock  USD 1.88  0.02  1.08%   
About 53% of MAIA Biotechnology's investor base is interested to short. The analysis of the overall investor sentiment regarding MAIA Biotechnology suggests that many traders are impartial. The current market sentiment, together with MAIA Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use MAIA Biotechnology stock news signals to limit their universe of possible portfolio assets.
  

MAIA Biotechnology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards MAIA Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at benzinga.com         
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From T...
benzinga news
over a year ago at news.google.com         
MAIA Biotechnology Patent Boosts Cancer Treatment Potential - TipRanks.com - TipRanks
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Acquisition by Vitoc Vlad of 200000 shares of MAIA Biotechnology subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer...
Google News at Macroaxis
over a year ago at finance.yahoo.com         
MAIA Soars 20 percent on Interim Results From Lung Cancer Study
Yahoo News
over a year ago at zacks.com         
MAIA Soars 20 percent on Interim Results From Lung Cancer Study
zacks News
over a year ago at finance.yahoo.com         
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines...
Yahoo News
over a year ago at news.google.com         
MAIA BIOTECHNOLOGY TO PRESENT AT BIOTECH SHOWCASE 2024 ON JANUARY 9, 2024 - Marketscreener.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
Yahoo News
over a year ago at news.google.com         
MAIA Biotechnology Significantly Undervalued With Novel Mechanism Impressive Early Data - Seeking Al...
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Acquisition by Smith Stan of 19273 shares of MAIA Biotechnology subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lu...
Google News at Macroaxis
over a year ago at news.google.com         
MAIA Biotechnology Stock , Quotes and News Summary - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Bears are Losing Control Over MAIA Biotechnology, Inc. MAIA ... - Yahoo Finance
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Bears are Losing Control Over MAIA Biotechnology, Inc. , Heres Why Its a Buy Now
Yahoo News
Far too much social signal, news, headlines, and media speculation about MAIA Biotechnology that are available to investors today. That information is available publicly through MAIA media outlets and privately through word of mouth or via MAIA internal channels. However, regardless of the origin, that massive amount of MAIA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MAIA Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MAIA Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MAIA Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MAIA Biotechnology alpha.

MAIA Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Maia Biotechnology director Steven Chaouki buys 55,553 in shares
11/04/2024
2
Director Steven Chaouki Acquires 22,133 Shares of MAIA Biotechnology Inc
11/05/2024
3
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
11/07/2024
4
Acquisition by Vitoc Vlad of 19982 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3
11/15/2024
5
Acquisition by Chaouki Steven M of 34641 shares of MAIA Biotechnology at 1.17 subject to Rule 16b-3
11/27/2024
6
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
12/03/2024
7
Acquisition by Guerrero Ramiro of 53418 shares of MAIA Biotechnology at 2.08 subject to Rule 16b-3
12/13/2024
8
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
12/19/2024
9
Acquisition by Theagene Jean-manasse of 10225 shares of MAIA Biotechnology at 1.98 subject to Rule 16b-3
12/31/2024
10
MAIA Biotechnology to Present at Biotech Showcase 2025
01/10/2025

Complementary Tools for MAIA Stock analysis

When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk